Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021 This bill allows audio-only diagnoses that are made via telehealth to be used for purposes of determining risk adjustments to payments under Medicare Advantage. Additionally, the bill requires payments for Medicare telehealth services that are furnished during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019) to be made in the same amounts as those for in-person services.
Focused Reduction of Effluence and Stormwater runoff through Hydrofracking Environmental Regulation Act of 2021 or the FRESHER Act of 2021 This bill addresses stormwater runoff from mining, oil, or gas operations. Specifically, it eliminates a prohibition on the Environmental Protection Agency from requiring a permit under the National Pollutant Discharge Elimination System for discharges of certain collected, uncontaminated stormwater runoff from mining operations or oil and gas operations. In addition, the Department of the Interior must study stormwater runoff associated with oil or gas operations, including an analysis of (1) measurable contamination, (2) groundwater resources, and (3) the susceptibility of aquifers to contamination from stormwater runoff associated with the operations.
CLEANER Act of 2021 or the Closing Loopholes and Ending Arbitrary and Needless Evasion of Regulations Act of 2021 This bill eliminates the exemption of waste associated with the exploration, development, or production of crude oil, natural gas, or geothermal energy from regulations governing the disposal of hazardous waste. Within a year of enactment, the Environmental Protection Agency (EPA) must determine whether such waste meets the criteria for hazardous waste, promulgate regulations concerning the disposal of such waste if the EPA determines it is hazardous, and revise regulations applicable to solid waste management and disposal facilities (e.g., landfills) to address such waste that is nonhazardous.
Medicare Drug Price Negotiation Act This bill makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs). Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations. If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the median price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost. Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.
Protecting Americans from Dangerous Algorithms Act This bill limits a social media company's immunity from liability if it promotes certain content on its platform. Specifically, the bill removes this immunity from a social media company with more than 10 million monthly users if it utilizes an algorithm, model, or other computational process to amplify or recommend content to a user that is directly relevant to a claim involving (1) interference with civil rights, (2) neglect to prevent interference with civil rights, or (3) acts of international terrorism.
Quit Because of COVID-19 Act This bill provides for Medicaid and Children's Health Insurance Program (CHIP) coverage of certain tobacco cessation services. Specifically, the bill provides for coverage, without cost-sharing, of diagnostic, therapy, and counseling services and pharmacotherapy, including prescription and nonprescription tobacco cessation agents, that are provided under medical supervision and in accordance with specified guidelines. It also applies a 100% Federal Medical Assistance Percentage (i.e., federal matching rate) for such items and services during the public health emergency relating to COVID-19 and for two years after the emergency period ends.
Minority Diabetes Initiative Act This bill authorizes grants for diabetes-related health care services in minority communities. The Department of Health and Human Services may make these grants to public and nonprofit health care providers.
Affordable Insulin for the COVID-19 Emergency Act This bill eliminates cost-sharing under the Medicare prescription drug benefit and Medicare Advantage for insulin and associated medical supplies during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019). The bill also allows beneficiaries to receive their insulin and supplies via mail order during the emergency period.
This resolution recognizes the disparity between wages paid to men and women, and its impact on women, families, and the nation and reaffirms Congress' commitment to supporting equal pay and to narrowing the gender wage gap.
This resolution expresses congressional disapproval of the rule submitted by the Equal Employment Opportunity Commission (EEOC) that revises the EEOC settlement process to provide employers with the factual and legal basis that the EEOC relied on to make a reasonable cause finding of a discriminatory practice.
Short on Competition Act This bill requires the Food and Drug Administration (FDA) to provide temporary authorization to import certain prescription drugs facing shortages or in a marginally competitive drug market. Specifically, the FDA shall authorize importation of an eligible drug that is lifesaving, life-sustaining, or intended to treat or prevent a debilitating condition. To be eligible, a drug must (1) be facing a shortage, (2) require a prescription, (3) have received market authorization in certain foreign countries, and (4) have the same active ingredient as the drug for which there is a shortage in the United States. The drug's manufacturer must also seek FDA approval for the drug as a generic drug. The import authorization shall be for three years or until the shortage no longer applies, whichever occurs first. Importation shall begin within 60 days of the FDA receiving an application that meets all of the applicable requirements. The FDA may deny importation of a drug for reasons related to safety or effectiveness. Drugs in marginally competitive markets must be treated as being in a shortage for the purposes of this bill and for the purposes of expedited inspections and review. A drug is in a marginally competitive market if (1) there are fewer than five holders of approved applications for commercially available brand-name or generic versions of the drug, (2) the drug has been approved for at least 10 years, and (3) the patents on the drug's active ingredients have expired.
Data Care Act of 20 21 This bill imposes various duties on online service providers with respect to their handling of individual-identifying data that can be reasonably linked to a specific user. Specifically, online service providers have a duty to (1) reasonably secure such data from unauthorized access, (2) refrain from using such data in a way that will result in reasonably foreseeable harm to the end user, and (3) not disclose such data to another party unless that party is also bound by the duties established in this bill. The bill authorizes the Federal Trade Commission and specified state officials to take enforcement actions with respect to breaches of such duties.
